Condition: Hepatocellular Carcinoma · Sponsor: Guangxi Medical University
This multicenter retrospective study which included patients with hepatocellular carcinoma (HCC) who received conversion or neoadjuvant therapy to explore the best treatment options and the best benefit group.
This description comes directly from the study's public registry record.
Jian-Hong Zhong, Ph.D · +86 771 5301253 · zhongjianhong66@163.com
Liang Ma, MD · +86 771 5301253 · malianggxyd@163.com
Always discuss trial participation with your own doctor first.
| Jian-Hong Zhong | Nanning, China, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06405321